AI Article Synopsis

  • * A cross-sectional study involving 42 patients with biopsy-proven LN used tools like the Lupus Quality of Life (LupusQoL) and the Compliance Questionnaire in Rheumatology 19 (CQR19) to evaluate HRQoL and medication adherence, defining non-adherence as taking less than 80% of their prescribed medication.
  • * Results showed that 60% of patients were

Article Abstract

Background: As with many other chronic diseases, systemic lupus erythematosus (SLE) and lupus nephritis (LN) have significant impacts on the health-related quality of life (HRQoL). Medication non-adherence is a significant challenge in the management of SLE, with consistently up to 75% of patients being non-adherent with their SLE medications. There is a need to assess the patient's perspective using patient-reported outcomes (PROs) to better understand the current impact of LN on HRQoL and treatment adherence in our region. The aim of this study was to explore the relationship between HRQoL and treatment adherence in patients with LN from the Colombian Caribbean.

Methods: A cross-sectional study was conducted from June to December 2022, including patients with biopsy-proven LN. HRQoL and treatment adherence were assessed using the Lupus Quality of Life (LupusQoL) and the Compliance Questionnaire in Rheumatology 19 (CQR19) instruments, respectively. Patients were categorized as adherent or non-adherent based on medication intake (defined as >80% correct dosage). Principal component analysis (PCA) was employed to identify principal components between adherent and non-adherent patients.

Results: A total of 42 patients with LN were included. Of these, 38 (90%) were female, and the mean age was 31 ± 10 years. Proliferative class IV was the predominant histopathological profile (90%). Twenty-five (60%) patients were categorized as non-adherent. Across all LupusQoL domains, a comprehensive range of responses was observed. Pain, planning, and intimate relationships domains remained unaffected, while burden to others domain had the lowest score. Poorer planning score correlated with older age (r = -0.72; < .05) and longer disease duration (r = -0.74; < .05). SLEDAI-2 K correlated with the pain domain (r = -0.78; < .05). Non-adherent patients exhibited significantly worse pain domain scores compared to adherent counterparts ( < .05). PCA showed strong interactions between planning and pain, as well as between physical health and body image domains.

Conclusions: LupusQoL pain domain scores were significantly worse in non-adherent patients compared to adherent patients. Effective pain management could be a determinant in HRQoL and treatment adherence rates in our population.

Download full-text PDF

Source
http://dx.doi.org/10.1177/09612033241280548DOI Listing

Publication Analysis

Top Keywords

treatment adherence
20
hrqol treatment
16
quality life
12
pain domain
12
patients
10
lupus nephritis
8
patients categorized
8
adherent non-adherent
8
non-adherent patients
8
domain scores
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!